|Dr. Jerry Kanellos Ph.D.||Interim CEO||175.2k||N/A||1961|
|Mr. Peter Anastasiou||Exec. Vice Chairman||42.5k||N/A||1960|
|Mr. Phillip Allen Hains||Joint CFO & Company Sec.||N/A||N/A||1959|
|Mr. Peter Vaughan BBus(Acc), CA||Joint CFO & Company Sec.||N/A||N/A||1983|
|Mr. David Lyon||Head of Marketing||N/A||N/A||N/A|
Immuron Limited, a biopharmaceutical company, focuses on the research and development of polyclonal antibodies for the treatment and prevention of various diseases in Australia and internationally. The company operates through Research and Development, and HyperImmune Products segments. It has a technology platform that produces antibodies to treat various diseases, including infectious diseases, cancers, and chronic inflammatory diseases. The company markets Travelan for the prevention of travellers' diarrhea. Its lead product candidate IMM-124E is in Phase II clinical trials for NASH and ASH. The company has a research and development collaboration agreement with the Walter Reed Army Institute of Research; and Naval Medical Research Center. Immuron Limited was founded in 1994 and is based in Blackburn North, Australia.
Immuron Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.